BPC-157: What the Research Actually Shows
A look at the animal data behind the internet's favorite recovery peptide, and the gap between preclinical promise and human evidence.
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid sequence derived from a peptide found in human gastric juice. It's become one of the most widely discussed research peptides for soft-tissue recovery, largely on the strength of a substantial body of rodent and in-vitro studies.
The mechanistic case is genuinely interesting: BPC-157 has been shown in animal models to promote angiogenesis (new blood vessel formation), upregulate growth factor receptors, and accelerate fibroblast migration in wound models. Rat studies on tendon-to-bone healing and gut lining repair are the most cited evidence base.
Where the evidence gets thinner is the jump to humans. As of today, there are no completed, peer-reviewed human clinical trials establishing safety or efficacy for BPC-157 in tendon, ligament, or gut-healing applications. Nearly everything written about human outcomes is anecdotal or extrapolated directly from rodent dosing, which is a meaningful gap when body size, metabolism, and injury context all differ.
The regulatory picture has also shifted: the FDA added BPC-157 to its list of substances that cannot be used in compounded drug products, citing insufficient safety data, which has pushed most legal sourcing into the 'research chemical, not for human consumption' category.
The honest summary: strong rodent mechanism data, zero completed human trials, and a regulatory posture that's grown more cautious rather than less. Anyone weighing this compound should treat the animal literature as a hypothesis, not a protocol.